For the past few years, the Institute for Clinical and Economic Review has filled an important void in the U.S. by assessing the extent to which new medicines — notably, high-priced treatments — may be cost effective. But a plan to charge drug makers for advice prior to product launches prompted skepticism from a Wall Street analyst who believes such a move would, if nothing else, help the pharmaceutical industry.
“This is a change from past practice where it relied on donations and conference organizing,” wrote Bernstein analyst Ronny Gal in an investor note. “We do not question ICER staff’s integrity, but it is very hard to not grow to like your clients. This funding mechanism is, respectfully, inherently problematic for an organization whose mission is to become the fair arbiter of drug value.”